IP Verse

Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6)

Patent No. EP2209491 (titled "Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6)") was filed by Novartis on Oct 31, 2008. The application was issued on Oct 28, 2015.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MERCK PATENTJul 28, 2016-
BOEHRINGER INGELHEIMJul 27, 2016D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2209491

NOVARTIS
Application Number
EP08844924A
Filing Date
Oct 31, 2008
Status
Revoked
Jun 10, 2022
Publication Date
Oct 28, 2015
External Links
Slate, Register , Google Patents